A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

This is a phase II clinical study to evaluate the safety and efficacy of pCAR-19 B cell autologous infusion preparation in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.

Trial Details

NCT ID
NCT05334823
Phase
PHASE2
Sponsor
Chongqing Precision Biotech Co., Ltd
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • pCAR-19B cells
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Shenzhen, Guangdong, China|22.54554,114.0683
  • Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

  • The patient himself or his guardian agrees to participate in this clinical trial and signs the Informed Consent Form (ICF), indicating that he unde…
  • Diagnosed with B-ALL，and meet one of the following conditions:
  • Refractory B-ALL: early-stage refractory patients who failed to achieve complete remission after 2 courses of standard induction chemotherapy;
  • Relapsed B-ALL: patients with early relapse (\<12 months) after complete remission;or late relapse (≥12 months) after complete remission, and relap…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →